Chronic Venous Occlusions Treatment Market - By Product (Devices {Compression Devices, Endogenous Ablation [Laser Ablation, Radiofrequency Ablation], Sclerotherapy, Vein Stripper}, Drugs), By Application (Varicose Veins), By End-use & Forecast, 2024 – 2032

Chronic Venous Occlusions Treatment Market Size

Chronic Venous Occlusions Treatment Market Size was valued at USD 6.6 billion in 2023 and is anticipated to witness growth at a CAGR of 5% between 2024 and 2032.
 

The chronic venous occlusions (CVO) treatment market is witnessing significant growth, fueled by rising awareness and advancements in medical technologies. With the global increase in the prevalence of chronic venous diseases, such as chronic venous insufficiency (CVI) and deep vein thrombosis (DVT), the demand for effective treatment options is escalating.
 

Recent trends show a significant shift towards minimally invasive procedures, such as endovenous laser therapy (EVLT) and radiofrequency ablation (RFA), which provide faster recovery times and lower risks compared to traditional surgery. The adoption of advanced imaging technologies like duplex ultrasound has further improved diagnostic accuracy and treatment planning, leading to better patient outcomes. Additionally, the increasing focus on personalized medicine has driven the development of tailored therapies based on individual patient profiles, enhancing treatment efficacy and patient care.
 

Pharmaceutical advancements are also making a significant impact, with the introduction of new anticoagulant and anti-inflammatory medications that complement procedural interventions. Additionally, the growing geriatric population, which is more susceptible to venous disorders, is fueling market growth. The expanding availability of innovative devices and technologies, along with supportive government policies and reimbursement schemes, is expected to further accelerate market expansion.
 

Chronic venous occlusions (CVO) treatment refers to medical interventions aimed at managing persistent blockages or insufficiencies in the venous system, commonly caused by conditions like chronic venous insufficiency (CVI) or deep vein thrombosis (DVT). Treatment options include conservative measures such as compression therapy, as well as more advanced procedures like endovenous laser therapy (EVLT), radiofrequency ablation (RFA), and surgical interventions to restore normal blood flow and alleviate symptoms. The goal of CVO treatment is to reduce venous pressure, improve circulation, and enhance the quality of life for individuals affected by venous disorders.
 

Chronic Venous Occlusions Treatment Market Trends

The increasing prevalence of varicose veins, coupled with rising awareness about its treatment, is significantly driving the chronic venous occlusions (CVO) treatment market. Varicose veins affect an estimated 25-30% of adults globally, with higher prevalence in women and aging populations. This growing incidence is amplifying the demand for effective treatment solutions.
 

• For instance, in the U.S., approximately 23 million people suffer from varicose veins, with a substantial proportion seeking medical intervention. Awareness campaigns and educational initiatives have played a crucial role in highlighting the availability of advanced treatment options. The rise in public awareness has been facilitated by both healthcare providers and patient advocacy groups, leading to increased consultations and early diagnosis.
• Furthermore, the advent of minimally invasive procedures such as endovenous laser therapy (EVLT) and radiofrequency ablation (RFA) has transformed the treatment landscape, offering patients effective options with reduced recovery times. The adoption of these technologies is supported by recent studies showing high success rates and patient satisfaction. For example, clinical data reveals that EVLT and RFA achieve over 90% success rates in treating varicose veins, contributing to their growing popularity.
   
• Additionally, the integration of advanced imaging techniques, such as duplex ultrasound, has enhanced diagnostic precision and treatment planning, further driving market growth. Government initiatives and insurance coverage expansions are also contributing to increased treatment accessibility. For instance, recent policy changes in several countries have improved reimbursement rates for varicose vein treatments, making them more affordable for patients.
   
• This combination of rising prevalence, heightened awareness, and technological advancements is expected to continue driving the CVO treatment market forward, as patients and healthcare systems increasingly prioritize effective management of chronic venous disorders.
   

Chronic Venous Occlusions Treatment Market Analysis

As per product, the market is classified into devices and drugs. The drugs segment is projected to exceed USD 5.1 billion by 2032.

• Various drugs are utilized in the diagnosis and therapy, including analgesics, antibiotics, anticoagulants, and so on. Antibiotics are highly preferred to treat ulcers and skin infections brought on by chronic venous insufficiency. Increasing prevalence of venous disorders, such as chronic venous insufficiency (CVI) and deep vein thrombosis (DVT), is fueling demand for effective pharmacological treatments. Advances in drug formulations, including novel anticoagulants and anti-inflammatory agents, are enhancing therapeutic efficacy and patient compliance.
   
• For instance, the development of direct oral anticoagulants (DOACs) offers improved safety and convenience over traditional treatments, driving their adoption. Additionally, growing awareness and diagnosis of venous diseases are contributing to higher drug utilization rates.
   
• Government and healthcare policies supporting drug reimbursement and access are further bolstering market growth. The emphasis on personalized medicine and targeted therapies is also promoting the development of innovative drugs tailored to individual patient needs, expanding treatment options.
   
• Furthermore, increased research and development investments in the pharmaceutical industry are accelerating the introduction of new drugs into the market, catering to unmet medical needs. Collectively, these drivers are expected to significantly boost the drugs segment of the CVO treatment market.
   

Based on application, the chronic venous occlusions treatment market is segmented into varicose veins, venous stasis ulcers, edema, deep vein thrombosis, and other applications. The edema application segment is expected to surpass a valuation of USD 2.9 billion by 2032.
 

• In 2021, a report in the PLOS Global Public Health Journal reported the prevalence of edema in around 19% of the American geriatric population. The mounting prominence of the numerous advantages offered by the available treatment options for chronic venous occlusion in the diagnosis and treatment of edema is expected to accelerate market trends.
   
• Rising prevalence of conditions like heart failure, kidney disease, and venous insufficiency, which frequently lead to edema, is increasing demand for effective treatments. Advances in pharmacological therapies, including diuretics and anti-inflammatory drugs, are improving management and treatment outcomes for patients with edema. Growing awareness about the impact of edema on quality of life is encouraging early diagnosis and treatment.
   
• Additionally, the aging population, which is more susceptible to chronic conditions that cause edema, is contributing to market growth. The development of innovative drug formulations and combination therapies designed to address underlying causes of edema is also driving segment expansion. These factors collectively support the significant growth of the edema application segment in the market.

• The Chronic Venous Occlusions Treatment market by end-use is segmented into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment dominated the market in 2023 and is predicted to rise rapidly during the forecast period.
   
• Hospitals serve as the primary centers for managing complex and severe cases of chronic venous disorders, including advanced varicose veins, deep vein thrombosis (DVT), and venous stasis ulcers. Their comprehensive diagnostic tools, specialized medical personnel, and advanced treatment technologies make them the preferred setting for chronic venous occlusion (CVO) management.
   
• The increasing prevalence of chronic venous diseases, combined with an aging population, is driving higher demand for hospital-based treatments. Hospitals are well-positioned to integrate multidisciplinary care approaches—combining surgical, pharmacological, and supportive therapies—which enhances treatment efficacy and patient outcomes. The advancement of medical devices and procedures, such as endovenous laser therapy (EVLT) and radiofrequency ablation (RFA), is further propelling growth within hospital settings.
   
• Growing healthcare expenditure and investments in hospital infrastructure to support advanced CVO treatments are also contributing to the segment's expansion. These factors collectively position hospitals as key players in the CVO treatment market, ensuring their continued dominance and growth.
   

North America chronic venous occlusions treatment market accounted for USD 2.7 billion in revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• A major driver of growth is the high prevalence of chronic venous diseases, such as varicose veins and deep vein thrombosis (DVT), which significantly affect the population. In the U.S., approximately 23 million people suffer from varicose veins, and nearly 900,000 cases of DVT are reported annually, underscoring the urgent need for effective treatments. The region's advanced healthcare infrastructure, including numerous specialized centers and hospitals, is well-equipped to manage complex cases, leading to increased treatment rates.
   
• The introduction and widespread adoption of minimally invasive procedures, such as endovenous laser therapy (EVLT) and radiofrequency ablation (RFA), are transforming the treatment landscape. These procedures offer quicker recovery times and fewer complications, with recent data indicating success rates exceeding 90%, driving their increased utilization.
   
• Government support through favourable reimbursement policies and health insurance coverage also plays a crucial role in making advanced treatments accessible to a broader population. Additionally, growing awareness and education about chronic venous disorders are leading to earlier diagnosis and intervention, which enhances treatment outcomes.
   
• The ongoing investments in research and development by pharmaceutical and medical device companies are fostering innovation and the introduction of new therapies. For example, the development of novel anticoagulants and anti-inflammatory medications is improving management options for conditions associated with CVO. Collectively, these factors contribute to the dynamic growth of the CVO treatment market in North America, positioning it as a leading region in the global market.
   

Japan chronic venous occlusions treatment market is projected to grow remarkably in the coming years.
 

• The chronic venous occlusion (CVO) treatment market in Japan is experiencing notable growth, fueled by the rising prevalence of venous disorders such as varicose veins and deep vein thrombosis (DVT). Japan's advanced healthcare system, combined with a growing elderly population, drives demand for effective and minimally invasive treatments. Technologies such as endovenous laser therapy (EVLT) and radiofrequency ablation (RFA) are gaining popularity due to their reduced recovery times and lower risk profiles.
   
• The Japanese government’s supportive reimbursement policies and investments in healthcare infrastructure further enhance the accessibility and adoption of these treatments. As awareness and early diagnosis improve, the CVO treatment market in Japan is poised for continued expansion.
   

Chronic Venous Occlusions Treatment Market Share

The market is highly fragmented due to the existence of multiple companies. New product releases, mergers and acquisitions, and the inclusion of cutting-edge technologies are among the core strategies being implemented by big corporations to strengthen their market position.
 

Chronic Venous Occlusions Treatment Market Companies

Some of the eminent market participants operating in the Chronic Venous Occlusions Treatment industry include:

• 3M Company
• Bayer AG
• Boston Scientific Corporation
• Bristol Myers Squibb
• Candela
• ConvaTec Inc.
• Fotona
• Julius Zorn GmbH
• Leucadia Pharmaceuticals (Hikma)
• Lumenis Ltd.
• Manufacturers viz.
• Medi GmbH & Co. KG
• Medtronic plc
• Merz Pharma
• Pfizer Inc.
• Sanofi
• Sciton, Inc
• Sigvaris AG
• Smith & Nephew PLC
• Stryker Corporation
• Tactile Medical
• Venclose, Inc. (Becton Dickinson and Company)
• Viatris Inc.

Chronic Venous Occlusions Treatment Industry News:

• In May 2022, THERACLION, a cutting-edge firm developing a scalable robotic platform for non-invasive echotherapy, introduced SONOVEIN HD. This groundbreaking technology integrates the advanced imaging capabilities of SuperSonic Imagine—recently acquired by Hologic—with the first and only extracorporeal therapeutic ultrasound solution, setting a new standard in non-invasive treatments.
   
• In April 2022, I-VASC, an Italian medical device manufacturer, has closed a EUR 1.8 million Series A investment to introduce its VELEX product. Designed for Empty Vein Ablation, VELEX targets chronic venous insufficiency (CVI) and varicose veins. The device was awarded CE marking in May 2021, marking a significant advancement in venous disorder treatments.
   

Chronic Venous Occlusions Treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Devices
  • Compression devices
  • Endovenous ablation
    • Laser ablation
    • Radiofrequency ablation
  • Sclerotherapy
  • Vein stripper
  • Other devices
• Drugs
  • Analgesics
  • Antibiotics
  • Anticoagulants
  • Other drugs

Market, By Application

• Varicose veins 
  • Venous stasis ulcers
  • Edema
  • Deep vein thrombosis
  • Other applications

Market, By End-use

• Hospitals
• Ambulatory Surgical Centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa